

**S2 Table. The numbers of subjects within each group reporting each related adverse event<sup>1</sup>**

Adverse events	Route	Aerosol Day 0	Intradermal Day 28	Intradermal Day 0	Aerosol Day 28	Intradermal Day 0	Intradermal Day 28
	<b>Group</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>3</b>
	<b>N</b>	<b>12</b>	<b>12</b>	<b>13<sup>2</sup></b>	<b>9<sup>3</sup></b>	<b>12</b>	<b>12</b>
<b>Solicited respiratory AEs</b>							
Chest pain		1 (8%)	0	0	5 (56%)	0	0
Haemoptysis		0	0	0	0	0	0
Coughing phlegm		0	0	2 (15%)	3 (33%)	3 (25%)	0
Shortness of breath		2 (17%)	0	1 (8%)	4 (44%)	1 (8%)	0
Wheeze		0	0	0	2 (22%)	2 (17%)	0
Sore throat		2 (17%)	2 (17%)	3 (23%)	2 (22%)	3 (25%)	5 (42%)
Cough		4 (33%)	2 (17%)	4 (31%)	7 (78%)	4 (33%)	5 (42%)
<b>Unsolicited respiratory AEs<sup>4</sup></b>							
Nasal congestion		1 (8%)	0	0	0	0	0
Rhinorrhoea		0	0	1(8%)	0	1 (8%)	1 (8%)
Face feeling swollen		0	0	0	1 (11%)	0	0
Chest discomfort		0	0	0	1 (11%)	0	0

---

**Solicited systemic AEs**

Malaise	3 (25%)	2 (17%)	4 (31%)	7 (78%)	1 (8%)	2 (17%)
Nausea	1 (8%)	1 (8%)	0	5 (56%)	1 (8%)	1 (8%)
Fatigue	5 (42%)	6 (50%)	3 (23%)	7 (78%)	5 (42%)	4 (33%)
Headache	5 (42%)	5 (42%)	6 (46%)	8 (89%)	4 (33%)	4 (33%)
Arthralgia	3 (25%)	2 (17%)	2 (15%)	4 (44%)	4 (33%)	1 (8%)
Myalgia	5 (42%)	6 (50%)	5 (38%)	7 (78%)	6 (50%)	4 (33%)
Felt feverish	2 (17%)	2 (17%)	3 (23%)	7 (78%)	3 (25%)	3 (25%)
Documented fever	2 (17%)	0	1 (8%)	6 (67%)	1 (8%)	0

**Unsolicited systemic AEs<sup>4</sup>**

Neck or Back pain	0	1 (8%)	0	1 (11%)	0	0
Chills	1 (8%)	0	0	0	0	0
Presyncope	0	0	2 (15%)	2 (22%)	0	0
Syncope	0	1(8%)	0	0	0	0
Insomnia	0	0	0	0	1 (8%)	0
Muscle spasm	0	0	0	0	0	1 (8%)

---

<b>Solicited local AEs</b>						
Local erythema	-	12 (100%)	13 (100%)	-	12 (100%)	12 (100%)
Local swelling	-	12 (100%)	13 (100%)	-	12 (100%)	12 (100%)
Local scaling	-	12 (100%)	13 (100%)	-	12 (100%)	8 (67%)
Local pain	-	11 (92%)	12 (92%)	-	11 (92%)	4 (100%)
Local pruritus	-	10 (83%)	12 (92%)	-	11 (92%)	9 (75%)
Local warmth	-	11 (92%)	12 (92%)	-	9 (75%)	8 (67%)
<b>Unsolicited local AEs<sup>4</sup></b>						
Axillary pain	-	0	2 (15%)	-	2 (17%)	1 (8%)
Lymphadenopathy	-	0	2 (15%)	-	0	1 (8%)
<b>Laboratory AEs<sup>5</sup></b>						
Anaemia	0	0	1 (11%)	0	0	0
Lymphopaenia	0	0	0	1 (11%)	0	0
Neutropaenia	0	0	0	1 (11%)	0	0

<sup>1</sup> All related adverse event data. Respiratory and solicited adverse event data shown for the first 7 days following each vaccination, as AEs following bronchoscopy at Day 7 were not deemed to be related. All adverse event data at the injection site and laboratory parameters data for 1 month period following each vaccination were deemed to be related.

<sup>2</sup> 3 placebo controls excluded from analysis

<sup>3</sup> Includes one subject who withdrew post first vaccination but prior to boost vaccination so was replaced

<sup>4</sup> Unsolicited symptoms are those deemed possibly, probably or definitely related to the vaccine

<sup>5</sup> All laboratory AEs were a maximum of Grade 1 severity